StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a research report released on Saturday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
Several other research firms also recently issued reports on ALIM. HC Wainwright restated a buy rating and set a $9.00 price objective on shares of Alimera Sciences in a report on Thursday. Alliance Global Partners cut Alimera Sciences from a buy rating to a neutral rating and lowered their target price for the company from $11.00 to $4.50 in a research note on Monday, November 21st.
Alimera Sciences Trading Down 5.3 %
NASDAQ ALIM opened at $2.26 on Friday. The stock’s 50-day moving average price is $2.58 and its two-hundred day moving average price is $4.36. The company has a market cap of $15.79 million, a PE ratio of -0.85 and a beta of 1.34. Alimera Sciences has a 1 year low of $2.03 and a 1 year high of $7.92.
Hedge Funds Weigh In On Alimera Sciences
About Alimera Sciences
Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- MarketBeat Week in Review – 2/20 – 2/24
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.